Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Mayo Clinic College of Medicine, Rochester, MN, USA.
J Bone Miner Res. 2019 Sep;34(9):1549-1551. doi: 10.1002/jbmr.3823. Epub 2019 Jul 25.
The public health implications of osteoporosis are enormous but the disease remains underdiagnosed and undertreated. In October 2018, the National Institutes of Health (NIH) convened a Pathways to Prevention (P2P) Workshop entitled "Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention" designed to identify research gaps, suggest future research opportunities, and advance the field through an evidence-based assessment. By design, the P2P report focused on "gaps" in our knowledge base. Unfortunately, however, the report did not sufficiently acknowledge the current evidence that unequivocally demonstrates the therapeutic efficacy of existing pharmacologic therapies for osteoporosis, which has the potential to exacerbate the current crises in osteoporosis diagnosis and treatment. © 2019 American Society for Bone and Mineral Research.
骨质疏松症对公众健康的影响巨大，但这种疾病仍然存在诊断不足和治疗不足的情况。2018 年 10 月，美国国立卫生研究院（NIH）召开了一个名为“预防途径（P2P）”的研讨会，题为“骨质疏松性骨折预防药物治疗的合理应用”，旨在确定研究差距，提出未来的研究机会，并通过循证评估推进该领域的发展。通过设计，P2P 报告侧重于我们知识基础上的“差距”。然而，不幸的是，该报告没有充分承认目前的证据，这些证据明确表明现有的骨质疏松症药物治疗具有疗效，这有可能加剧目前骨质疏松症诊断和治疗方面的危机。 © 2019 美国骨骼与矿物质研究协会。
